Sitagliptin, Glipizide Monotherapy Safe, Effective In Patients With T2D And ESRD Requiring Dialysis.

Renal and Urology News  (1/30, Charnow) reports, "Sitagliptin and glipizide monotherapy is safe and effective in patients with type 2 diabetes and end-stage renal disease (ESRD) requiring dialysis, researchers reported online ahead of print in the American Journal of Kidney Diseases." Investigators came to this conclusion after conducting a "54-week, randomized, double-blind study" that "included 129 patients with type 2 diabetes and ESRD requiring dialysis."